Latest Healthcare Research Reports

Tag: cancer anorexia cachexia syndrome market size

  • Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Is Reshaping Competitive Advantage Across The Industry

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Is Reshaping Competitive Advantage Across The Industry

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

    The market for cancer anorexia-cachexia syndrome (cacs) has experienced significant expansion recently. Projections indicate a continued upward trajectory, with the market value anticipated to ascend from $3.88 billion in 2025 to $4.29 billion in 2026, reflecting a compound annual growth rate of 10.7%. Factors contributing to this growth during the preceding period include a rise in advanced cancer diagnoses, heightened awareness of how cachexia affects treatment success, the initial implementation of appetite-enhancing medications, the proliferation of supportive care initiatives within healthcare facilities, and advancements in research concerning nutrition for cancer patients.

    The market for cancer anorexia-cachexia syndrome (CACS) is poised for significant expansion in the coming years, projected to reach $6.37 billion by 2030 with a compound annual growth rate (CAGR) of 10.4%. This anticipated surge is fueled by several key factors, including escalating investments in the development of cachexia therapeutics, a heightened emphasis on tailored supportive care within oncology, increased engagement in clinical trials for innovative treatments, the broader availability of home-based cancer care services, and a more integrated approach to cachexia management within established oncology treatment plans. During this forecast period, prominent trends will involve a greater concentration on developing targeted therapies for cachexia, a growing interest in addressing anti-inflammatory pathways, a more widespread embrace of combination treatment strategies, advancements in nutritional and metabolic support offerings, and a stronger imperative for proactive intervention in managing cachexia.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Factors Supporting Long-Term Expansion

    The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the cancer anorexia-cachexia syndrome market. Cancer, a classification of illnesses marked by the uncontrolled proliferation and dissemination of aberrant cells, is experiencing a global upswing attributable to an aging demographic, shifts in lifestyle habits, environmental influences, enhanced diagnostic capabilities, and heightened awareness, in addition to inherited predispositions and infections associated with particular cancers. The cancer anorexia-cachexia syndrome (CACS) plays a crucial role in addressing this growing cancer burden by concentrating on the management of profound weight loss and malnutrition commonly afflicting cancer patients, thereby enhancing their overall well-being and therapeutic results. Illustrating this trend, a report released in August 2024 by Macmillan Cancer Support, a philanthropic organization in the UK, indicated that more than 3 million individuals in the UK are currently diagnosed with cancer, a figure projected to reach 3.5 million by 2025, 4 million by 2030, and a substantial 5.3 million by 2040. Consequently, the increasing prevalence of cancer is a primary driver for the cancer anorexia-cachexia syndrome market.

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Driver: Impact Of Increasing Healthcare Expenditure On The Market

    A surge in healthcare spending is poised to fuel the advancement of the cancer anorexia-cachexia syndrome market. Healthcare expenditure encompasses the aggregate financial outlays dedicated to health services, encompassing both public and private sector investments. This upward trend in healthcare expenditure is propelled by factors such as an aging global population, a rising tide of chronic illnesses, breakthroughs in medical technology, and a greater demand for high-quality medical care. Cancer Anorexia-Cachexia Syndrome (CACS) contributes to this escalating healthcare expenditure by necessitating specialized treatment protocols, dedicated nutritional support, and palliative care services for affected individuals, thereby increasing the overall cost associated with managing cancer’s complications. As an illustration, data from the Office for National Statistics, a UK governmental body, revealed in May 2024 that total healthcare expenditure experienced a 5.6% nominal increase between 2022 and 2023, representing a considerable acceleration from the 0.9% growth recorded in 2022. Therefore, burgeoning healthcare expenditure is a key driver for the cancer anorexia-cachexia syndrome market.

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Categorization By Product Type And Application

    The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Industry Trends Shaping Future Revenue Growth

    Leading entities within the cancer anorexia-cachexia syndrome market are prioritizing the creation of novel therapeutic approaches, exemplified by monoclonal antibody treatments, with the overarching goals of boosting treatment effectiveness, achieving better patient results, and fulfilling existing gaps in clinical care. These monoclonal antibody therapies involve the utilization of antibodies manufactured in a lab, specifically engineered to identify and bind to particular markers on cancerous cells, thereby empowering the body’s immune defenses to more accurately detect and combat these malignant cells. A noteworthy development occurred in September of 2024 when Pfizer Inc., a prominent American firm in the pharmaceutical and biotechnology sectors, disclosed favorable findings from its Phase II clinical investigation of ponsegromab, a monoclonal antibody designed to inhibit Growth/Differentiation Factor 15 (GDF-15). The encouraging data emerging from this research signifies a promising new therapeutic pathway for individuals afflicted by this severe condition, for which treatment options are presently scarce. Evidence from the Phase 2 study indicates substantial advancements in mitigating the inflammatory mechanisms that contribute to muscle wasting and weight reduction in individuals battling cancer. This therapeutic strategy is intended to not only restore physical capabilities but also to elevate the general well-being and quality of life experienced by cancer patients, representing a crucial advancement in the field of cancer treatment.

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Company Landscape And Strategic Competition

    Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Access The Complete Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Geographic Analysis: Where Is Demand Growing The Fastest?

    North Americawas the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Outlook Indicating Expansion To $6.37 Billion By 2030

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Outlook Indicating Expansion To $6.37 Billion By 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market Change Between 2026 And 2030?

    The cancer biopsy market has seen swift growth in recent years. It is anticipated to expand from $28.52 billion in 2025 to $32.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. This historical development can be ascribed to several factors, including the increasing global occurrence of cancer, the proliferation of diagnostic imaging centers, the integration of tissue biopsy as a standard diagnostic procedure, the expansion of pathology laboratory networks, and enhancements in biopsy device technologies.

    The cancer biopsy market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $53.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This growth during the projected timeframe is attributable to a heightened demand for precision oncology diagnostics, increased uptake of liquid biopsy testing, the broadening of personalized cancer treatment strategies, expanding investments in molecular diagnostics, and a sharpened emphasis on early-stage cancer screening. Key trends anticipated for this period encompass the growing integration of liquid biopsy methods, an uptick in the utilization of image-guided biopsy procedures, an expanding incorporation of molecular pathology testing, the development of minimally invasive biopsy devices, and an intensified focus on identifying cancer early.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    What Important Drivers Are Powering The Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth?

    The rising incidence of cancer is predicted to fuel the expansion of the cancer biopsy market moving ahead. Cancer is a complex assortment of diseases defined by the abnormal proliferation and dissemination of cells. This rise in cancer cases can be attributed to multiple elements, such as evolving lifestyles and urbanization, environmental contamination, tobacco and alcohol consumption, and differences in healthcare access and awareness. A cancer biopsy serves to diagnose and evaluate the cancer’s type, stage, and spread through the extraction and analysis of tissue or cells from a suspicious zone. For instance, in February 2024, the World Health Organization, an intergovernmental organization located in Switzerland, projected that by 2050, more than 35 million new cancer cases would arise, marking a 77% increase over the estimated 20 million cases in 2022. Thus, the escalating prevalence of cancer acts as a significant impetus for the cancer biopsy market.

    What Are The Major Segment Categories Within The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    What Trends Are Affecting The Growth Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Leading companies in the cancer biopsy market are actively developing liquid biopsy techniques. These advancements aim to enable non-invasive, early detection and monitoring of cancer, improve patient outcomes, and facilitate more personalized treatment approaches. Liquid biopsy is a sophisticated, non-invasive diagnostic method that identifies and analyzes genetic material from blood samples, including circulating tumor DNA (ctDNA), RNA, exosomes, and other biomarkers. For example, in May 2023, Labcorp, a US-based company specializing in cancer biopsy manufacturing, launched Labcorp Plasma Focus, a plasma-focused liquid biopsy designed to detect cancer-related biomarkers. The Plasma Focus test examines circulating cell-free DNA (cfDNA) released from tumor cells into the bloodstream, capable of constructing a genomic profile of the patient’s tumor and identifying mutations across 33 genes linked to various cancers, such as non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

    Which Firms Are Competing In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Access The Complete Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Geographic Region Represents The Largest Cancer Anorexia-Cachexia Syndrome (CACS) Market Share?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Cancer Anorexia-Cachexia Syndrome (CACS) Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company

    Anaphylaxis Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

    Vulvodynia Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

    Emphysema Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global cancer anorexia-cachexia syndrome market to reach $6.37B by 2030 at 10.4% CAGR

    Global cancer anorexia-cachexia syndrome market to reach $6.37B by 2030 at 10.4% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    From Its 2026 Market Size, What Value Is The Cancer Anorexia-Cachexia Syndrome (CACS) Market Projected To Reach By 2030?

    The cancer anorexia-cachexia syndrome (cacs) market has experienced rapid expansion in recent years. It is projected to grow from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This growth observed in previous periods can be linked to the increasing occurrence of advanced cancer cases, a heightened awareness of cachexia’s effect on treatment results, the initial clinical deployment of appetite stimulants, the development of hospital-based supportive care initiatives, and the broadening of oncology nutrition research.

    The market for cancer anorexia-cachexia syndrome (cacs) is projected to experience substantial expansion over the upcoming years, anticipated to reach $6.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this projected growth include rising investments in developing cachexia drugs, an increasing emphasis on personalized oncology supportive care, heightened clinical trial activity for new therapeutic agents, the broadening of home-based cancer care services, and the greater incorporation of cachexia management within oncology protocols. Key trends anticipated during this period involve the intensified development of targeted therapies for cachexia, a greater concentration on anti-inflammatory treatment methods, the increasing implementation of combination therapeutic strategies, an expansion of nutritional and metabolic support options, and a stronger focus on early intervention for cachexia.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Strong Drivers Are Impacting The Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth?

    The increasing incidence of cancer is anticipated to drive the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer is a broad term for a range of diseases marked by the uncontrolled multiplication and spread of abnormal cells within the body. Global cancer rates are on the rise due to various factors, including an aging population, shifts in lifestyle, environmental exposures, advancements in detection methods, heightened public awareness, along with genetic predispositions and infections linked to specific cancers. Cancer anorexia-cachexia syndrome (CACS) addresses this growing cancer prevalence by concentrating on managing the severe weight loss and malnutrition frequently observed in cancer patients, thereby improving their overall quality of life and treatment outcomes. For instance, in August 2024, a report from the UK-based charitable organization Macmillan Cancer Support revealed that over 3 million people in the UK are living with cancer, a number projected to grow to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is a key driver for the growth of the cancer anorexia-cachexia syndrome market.

    How Is Segmentation Applied In The Cancer Anorexia-Cachexia Syndrome (CACS) Market Segment Analysis?

    The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    Which Trends Are Contributing To Changes In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Leading companies in the cancer anorexia-cachexia syndrome market are concentrating on developing innovative solutions, such as monoclonal antibody therapies, to improve treatment effectiveness, enhance patient outcomes, and address existing clinical needs. Monoclonal antibody treatments involve the use of laboratory-produced antibodies engineered to target specific antigens on cancer cells, thereby helping the immune system more effectively identify and attack them. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial for ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The promising data from this study provides hope for a novel treatment approach for patients suffering from this debilitating condition, for which few effective therapies currently exist. The Phase 2 trial results indicate significant progress in addressing the underlying inflammatory processes that contribute to muscle loss and weight decline in cancer patients. This treatment approach aims to not only improve physical function but also to enhance the overall quality of life for cancer patients, marking a crucial step in oncology care.

    Who Are The Companies Participating In The Cancer Anorexia-Cachexia Syndrome (CACS) Market Environment?

    Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Get The Full Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Region Is The Leading Market For The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Cancer Anorexia-Cachexia Syndrome (CACS) Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company

    Progressive Ataxia And Weakness Disorders Market Report 2026

    https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

    Anorectal Disorders Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report

    Oncology Nutrition Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Set for Strong Expansion Reaching $6.37 Billion by 2030 at 10.4% CAGR

    Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Set for Strong Expansion Reaching $6.37 Billion by 2030 at 10.4% CAGR

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Will Be The Estimated Market Valuation Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market By The End Of 2030?

    The market for cancer anorexia-cachexia syndrome (CACS) has seen rapid expansion over recent years. It is forecast to rise from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This growth historically stems from factors including the increasing occurrence of advanced cancer cases, a heightened understanding of cachexia’s effect on treatment results, the early adoption of appetite stimulants in clinical practice, an increase in hospital-based supportive care initiatives, and the broadening of oncology nutrition research.

    The market for cancer anorexia-cachexia syndrome (cacs) is projected to experience substantial expansion over the upcoming years, with an anticipated value of $6.37 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.4%. This projected growth is driven by factors such as increased funding for cachexia drug development, a heightened emphasis on personalized oncology supportive care, greater activity in clinical trials for new therapeutic agents, the broadening of home-based cancer care services, and the deeper incorporation of cachexia management strategies into standard oncology protocols. Key trends anticipated during this period encompass the development of more targeted therapies for cachexia, a growing interest in anti-inflammatory treatment methods, wider acceptance of combination therapeutic strategies, the proliferation of nutritional and metabolic support options, and a stronger focus on early intervention for cachexia.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The growing incidence of cancer is expected to drive the expansion of the **cancer anorexia-cachexia syndrome market** in the future. Cancer is a broad categorization for diseases characterized by the unrestrained proliferation and dissemination of abnormal cells throughout the body. Global cancer rates are increasing due to elements like an aging demographic, shifts in lifestyle, environmental exposures, improved detection methodologies, and greater awareness, alongside genetic predispositions and infections linked to certain cancer types. **Cancer anorexia-cachexia syndrome (CACS)** helps tackle this rising cancer prevalence by concentrating on addressing the severe weight loss and malnutrition frequently experienced by cancer patients, thereby enhancing their overall quality of life and treatment outcomes. For instance, in August 2024, a report released by Macmillan Cancer Support, a charitable organization in the **UK**, stated that over **3 million** individuals in the **UK** are living with cancer, a figure projected to climb to **3.5 million** by **2025**, **4 million** by **2030**, and **5.3 million** by **2040**. Thus, the increasing prevalence of cancer is a key factor stimulating the growth of the **cancer anorexia-cachexia syndrome market**. Increasing healthcare expenditure is anticipated to propel the growth of the **cancer anorexia-cachexia syndrome market** moving forward. Healthcare expenditure refers to the aggregate financial resources allocated to healthcare services, encompassing both public and private sector spending. The rise in healthcare expenditure is driven by factors such as an aging population, the increasing incidence of chronic diseases, advancements in medical technology, and a heightened demand for high-quality healthcare services. **Cancer Anorexia-Cachexia Syndrome (CACS)** contributes to increasing healthcare expenditure by requiring specialized treatments, nutritional support, and palliative care for patients, thereby adding to the costs associated with managing cancer-related complications. For example, in May 2024, according to the Office for National Statistics, a **UK**-based government department, total healthcare expenditure recorded a **5.6%** increase in nominal terms from **2022** to **2023**, indicating a notable acceleration compared to the **0.9%** growth observed in **2022**. Consequently, the increasing healthcare expenditure is driving the expansion of the **cancer anorexia-cachexia syndrome market**.

    Which Segment Classifications Shape The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    What Key Trends Are Influencing The Development Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Leading companies within the cancer anorexia-cachexia syndrome market are prioritizing the development of innovative solutions, such as monoclonal antibody therapies, to improve the effectiveness of treatments, enhance patient well-being, and address unmet needs in clinical practice. Monoclonal antibody therapies are medical interventions that employ antibodies manufactured in a laboratory setting, specifically designed to target unique antigens on cancer cells, thereby helping the immune system to recognize and attack them more vigorously. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial involving ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The encouraging data from this study presents new hope for a treatment option for patients grappling with this debilitating condition, for which there are currently few efficacious treatments available. The Phase 2 trial’s findings indicate substantial progress in addressing the underlying inflammatory processes that contribute to muscle wasting and weight loss among cancer patients. This particular treatment approach aims not only to enhance physical function but also to elevate the overall quality of life for cancer patients, marking a significant advancement in oncology care.

    Which Companies Are Expanding Their Footprint In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Read the full cancer anorexia-cachexia syndrome (cacs) market report here:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Regions Are Projected To Dominate The Cancer Anorexia-Cachexia Syndrome (CACS) Market In The Coming Years?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Cancer Anorexia-Cachexia Syndrome (CACS) Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company

    Anaphylaxis Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

    Vulvodynia Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

    Emphysema Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Anorexia-Cachexia Syndrome (CACS) Market Forecast: How Big Will It Be by 2030?

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Forecast: How Big Will It Be by 2030?

    Uncover key drivers, emerging technologies, and competitive movements shaping the cancer anorexia-cachexia syndrome (cacs) market from 2026–2035 with trusted insights from The Business Research Company

    Across 2026–2030, what is the expected market valuation path of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs) market has experienced rapid growth over recent years. Its valuation is expected to increase from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This historic growth can be attributed to several factors including the rising prevalence of advanced cancer cases, an increased understanding of cachexia’s influence on treatment outcomes, the early adoption of appetite stimulants in clinical settings, the proliferation of hospital-based supportive care programs, and the expansion of research in oncology nutrition.

    The market for cancer anorexia-cachexia syndrome (CACS) is projected to experience swift expansion in the coming years. This market is anticipated to reach a valuation of $6.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the projected timeframe include greater financial commitments to developing cachexia drugs, an increasing emphasis on personalized supportive care in oncology, intensified clinical trial efforts for new therapeutic agents, the broadening availability of cancer care delivered at home, and the enhanced incorporation of cachexia management strategies into standard oncology protocols. Key trends anticipated during this period encompass the escalating creation of targeted treatments for cachexia, a heightened interest in anti-inflammatory therapeutic routes, the increasing embrace of combined treatment methodologies, the widening scope of nutritional and metabolic support options, and a stronger focus on intervening in cachexia at an earlier stage.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    Which Drivers Are Supporting The Rise Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The increasing incidence of cancer is anticipated to fuel the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer encompasses a range of illnesses characterized by the unchecked proliferation and dissemination of abnormal cells within the body. The global rise in cancer rates can be attributed to various factors, including an aging demographic, shifts in lifestyle, exposure to environmental hazards, enhanced diagnostic techniques, increased public awareness, alongside genetic predispositions and specific infection-related cancers. Cancer anorexia-cachexia syndrome (CACS) plays a crucial role in addressing this increasing cancer burden by focusing on the management of severe weight loss and malnutrition frequently observed in cancer patients, thereby enhancing their overall quality of life and improving treatment outcomes. For instance, a report from Macmillan Cancer Support, a UK-based charitable organization, released in August 2024, indicated that more than 3 million individuals in the UK are currently living with cancer, a figure projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer acts as a key driver for the growth of the cancer anorexia-cachexia syndrome market.

    What Leading Segments Are Studied In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    How Are New Market Trends Shaping The Landscape Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Major companies operating within the cancer anorexia-cachexia syndrome market are prioritizing the creation of innovative solutions, including monoclonal antibody therapies, to elevate treatment efficacy, enhance patient outcomes, and fill unmet clinical requirements. Monoclonal antibody therapies are a form of treatment utilizing laboratory-engineered antibodies specifically designed to target distinct antigens present on cancer cells, thereby aiding the immune system in recognizing and combating them more effectively. As an illustration, in September 2024, Pfizer Inc., a pharmaceutical and biotechnology corporation based in the US, announced positive results from a Phase II clinical trial concerning ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The favorable data from this study provides optimism for a novel treatment approach for patients afflicted with this debilitating condition, given the current scarcity of effective therapies. The Phase 2 trial outcomes indicate significant progress in addressing the fundamental inflammatory processes that contribute to muscle deterioration and weight reduction in cancer patients. This therapeutic strategy seeks not only to improve physical functionality but also to uplift the overall quality of life for individuals with cancer, marking a crucial progression in oncology treatment.

    Which Major Firms Are Strengthening Their Position In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Region Is Anticipated To See The Fastest Growth In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Cancer Anorexia-Cachexia Syndrome (CACS) Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company

    Progressive Ataxia And Weakness Disorders Market Report 2026

    https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

    Anorectal Disorders Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report

    Oncology Nutrition Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Long-Term Forecast For The Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Growing At 10.5% CAGR?

    What Is The Long-Term Forecast For The Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Growing At 10.5% CAGR?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Is The Predicted Market Size Of The Cancer Anorexia-Cachexia Syndrome (CACS) Industry By 2029?

    The market for the cancer anorexia-cachexia syndrome (CACS) has expanded swiftly in recent years. It is projected to rise from a $3.51 billion value in 2024 to approximately $3.88 billion by 2025, with a compound annual growth rate (CAGR) pegged at 10.7%. Factors such as an increase in cancer occurrences, heightened awareness among healthcare providers, an emphasis on improving the life quality of cancer patients, growth in clinical trials, and collaborations and partnerships in the pharmaceutical field have contributed to the growth noted in the historical period.

    Expectations are high for a swift expansion in the cancer anorexia-cachexia syndrome (cacs) market in the upcoming years. The market is predicted to touch the $5.79 billion mark by 2029, exhibiting a compound annual growth rate (CAGR) of 10.5%. The projected growth during this period is attributed to factors including improved cancer survival rates, an upward trend in investments related to oncology supportive care, advancement in personalized medicine, an intensified focus on multimodal therapies, and enhancing healthcare infrastructure. The future period will likely witness significant trends such as progression in palliative care, creation of targeted therapies, innovative advancements in drug delivery systems, the integration of AI in drug development, and the expansion of personalized medicine.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    Which Factors Are Steering Growth In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The escalating occurrence of cancer is anticipated to drive the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer encompasses a wide range of diseases marked by the unchecked proliferation and dissemination of anomalous cells within the human body. Globally, cancer instances are on the rise due to elements such as an aging demographic, alterations in lifestyles, environmental influences, advancements in detection techniques, heightened awareness, as well as genetic susceptibilities and infections linked to specific types of cancer. Cancer anorexia-cachexia syndrome’s (CACS) primary aim is to manage the pronounced weight reduction and malnutrition frequently observed in cancer patients, thereby enhancing their overall quality of life and treatment results. Take, for example, a report released in August 2024 by Macmillan Cancer Support, a UK-based charity, that pointed out the cancer prevalence in the UK, with over 3 million people battling the disease. The report projected an increase in this number to 3.5 million by 2025, reaching 4 million by 2030, and finally touching 5.3 million by 2040. Consequently, the escalating occurrence of cancer is fueling the expansion of the cancer anorexia-cachexia syndrome market.

    Which Segment Accounts For The Largest Share In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs)market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications

    2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions

    4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration

    5) By Application: Hospitals; Clinics; Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors

    5) By Other Indications: Combination Therapies; Supportive Care Interventions

    What Strategic Shifts And Innovations Are Influencing The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Leading businesses in the cancer anorexia-cachexia syndrome market are prioritizing the creation of novel solutions like monoclonal antibody therapies. These solutions aim to increase the effectiveness of treatments, improve patient prognosis, and fulfill unresolved clinical requirements. The therapies involve using lab-developed antibodies that aim at specific antigens on cancer cells, thus aiding the immune system in identifying and more efficiently attacking these cells. Pfizer Inc., a pharmaceutical and biotech firm based in the US, for instance, reported encouraging results from a Phase II study for ponsegromab, a monoclonal antibody that targets Growth/Differentiation Factor 15 (GDF-15) in September 2024. The promising data from the trial paves the way for a fresh treatment path for individuals suffering from this distressing condition, as there are currently very few effective treatments available. The Phase 2 trial results indicate significant advancements in tackling the underlying inflammatory causes leading to muscle atrophy and weight reduction in cancer patients. The focus of this treatment strategy isn’t only to enhance physical function but also to improve the general life quality of cancer patients—an important breakthrough in cancer treatment.

    Who Are The Dominant Players In The Cancer Anorexia-Cachexia Syndrome (CACS) Market Today?

    Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    What Regional Factors Are Accelerating Growth In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2025, By The Business Research Company

    Cancer Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Bladder Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

    Blood Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends and Growth Analysis 2025–2029

    Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends and Growth Analysis 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    By How Much Is The Cancer Anorexia-Cachexia Syndrome (CACS) Market Expected To Expand Between 2025 And 2029?

    The market for cancer anorexia-cachexia syndrome (cacs) has experienced significant expansion recently. Projections indicate its value will increase from $3.51 billion in 2024 to $3.88 billion by 2025, reflecting a compound annual growth rate (CAGR) of 10.7%. Historically, this growth can be ascribed to factors such as an escalating incidence of cancer, enhanced awareness among medical practitioners, a heightened emphasis on improving the quality of life for cancer patients, the broadening scope of clinical trials, and strategic pharmaceutical collaborations and partnerships.

    The cancer anorexia-cachexia syndrome (CACS) market size is set for considerable growth over the next few years. It is projected to reach $5.79 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.5%. This expansion during the forecast period can be attributed to factors like improved cancer survival rates, increasing investments in oncology supportive care, the rise of personalized medicine, a growing emphasis on multimodal therapies, and expanding healthcare infrastructure. Key developments expected during this period include advancements in palliative care, the emergence of targeted therapies, technological innovations in drug delivery systems, the integration of AI in drug development processes, and the further evolution of personalized medicine.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The escalating prevalence of cancer is anticipated to propel the cancer anorexia-cachexia syndrome market’s growth moving forward. Cancer, a broad term for diseases marked by uncontrolled growth and spread of abnormal cells, is seeing a global rise in rates. This increase is driven by factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, and heightened awareness, alongside genetic predispositions and infections linked to certain cancers. Cancer anorexia-cachexia syndrome (CACS) helps address this growing cancer burden by focusing on managing the severe weight loss and malnutrition often observed in cancer patients, thereby enhancing their overall quality of life and treatment outcomes. For instance, in August 2024, a report by the UK-based charitable organization Macmillan Cancer Support indicated that over 3 million people in the UK are living with cancer, a number expected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the expanding prevalence of cancer directly drives the growth of the cancer anorexia-cachexia syndrome market.

    What Are The Leading Segments Analyzed In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The cancer anorexia-cachexia syndrome (cacs)market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications

    2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions

    4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration

    5) By Application: Hospitals; Clinics; Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors

    5) By Other Indications: Combination Therapies; Supportive Care Interventions

    How Are Emerging Market Trends Shaping The Cancer Anorexia-Cachexia Syndrome (CACS) Industry Landscape?

    Leading companies operating within the cancer anorexia-cachexia syndrome market are concentrating on creating novel solutions, including monoclonal antibody therapies, to boost treatment effectiveness, better patient results, and fulfill outstanding clinical requirements. These monoclonal antibody therapies utilize laboratory-produced antibodies crafted to target specific antigens on cancerous cells, thus assisting the immune system in identifying and combating them more efficiently. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, disclosed favorable outcomes from its Phase II clinical trial for ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The encouraging data from this research provides promise for an alternative treatment path for individuals suffering from this severe condition, given the current scarcity of effective treatments. The findings from the Phase 2 trial indicate substantial advancement in tackling the fundamental inflammatory mechanisms that lead to muscle wastage and weight reduction in cancer patients. This therapeutic strategy seeks not only to improve physical capabilities but also to uplift the general quality of life for those with cancer, representing a crucial development in oncology care.

    Which Major Firms Are Strengthening Their Position In The Cancer Anorexia-Cachexia Syndrome (CACS) Industry?

    Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    Which Regional Markets Are Contributing Most To The Cancer Anorexia-Cachexia Syndrome (CACS) Industry Expansion?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2025, By The Business Research Company

    Cancer Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Bladder Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

    Blood Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Current and Projected Market Size of the Cancer Anorexia-Cachexia Syndrome (CACS) Market Through 2034?

    The market for the cancer anorexia-cachexia syndrome (cacs) has seen dynamic expansion in the past few years. With a progression from $3.51 billion in 2024, it is anticipated to climb up to $3.88 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.7%. Factors influencing this advancement in the historic period include the escalating occurrence of cancer, heightened cognizance among medical professionals, an emphasis on improving life quality for cancer patients, widening of clinical trials, and the increase in cooperative efforts and alliances in the pharmaceutical sector.

    The market size for the cancer anorexia-cachexia syndrome (cacs) is projected to experience swift expansion in the upcoming years, with a valuation predicted to reach$5.79 billion in 2029″ at a compound annual growth rate (CAGR) of 10.5%. The momentum during the forecast period can be credited to improved cancer survival rates, growing investment in oncology support care, advancements in personalized medicine, intensified focus on multimodal treatments, and the developing health care infrastructure. The forecast period will also witness major trends such as progress in palliative care, the creation of focused therapies, technological innovation in drug delivery systems, incorporation of AI in drug formation, and tailor-made medicine.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    What Are the Major Market Drivers Behind the Rising Adoption of Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The expected rise in cancer cases is projected to steer the expansion of the cancer anorexia-cachexia syndrome market. This encompasses a range of diseases marked by uninhibited cell proliferation and spread within the body, broadly defined as cancer. The increasing global incidence of cancer is due to a multitude of factors such as an aging demographic, modifications in lifestyle, environmental factors, enhanced methods of detection, increased awareness, genetic susceptibility, and infections associated with specific cancer types. The cancer anorexia-cachexia syndrome (CACS) assists in managing severe weight loss and malnutrition commonly associated with cancer patients, aiming to better their general life quality and treatment results. For example, a study released by Macmillan Cancer Support, a UK charity, in August 2024 indicated that over 3 million people have cancer in the UK. This statistic is predicted to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the surge in cancer incidence is pushing the expansion of the cancer anorexia-cachexia syndrome market.

    Which Key Market Segments Comprise the Cancer Anorexia-Cachexia Syndrome (CACS) Market and Drive Its Revenue Growth?

    The cancer anorexia-cachexia syndrome (cacs)market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications

    2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions

    4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration

    5) By Application: Hospitals; Clinics; Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors

    5) By Other Indications: Combination Therapies; Supportive Care Interventions

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Which Areas Are Leading Regions in the Cancer Anorexia-Cachexia Syndrome (CACS) Market Expansion Across the Globe?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Strategic Trends Steering theCancer Anorexia-Cachexia Syndrome (CACS) Market Direction?

    Predominant corporations in the field of the cancer anorexia-cachexia syndrome market are centering their efforts on creating novel solutions, such as monoclonal antibody therapies. These therapies are expected to increase the effectiveness of treatments, raise patient outcomes, and answer unsatisfied clinical requirements. Monoclonal antibody therapies consist of treatments that employ antibodies produced in a lab designed to target unique antigens on cancer cells, enabling the immune system to identify and counter them more efficiently. For instance, Pfizer Inc., a pharmaceutical and biotechnology entity based in the US, reported positive findings from a Phase II clinical trial of ponsegromab, a monoclonal antibody aiming at Growth/Differentiation Factor 15 (GDF-15) in September 2024. The encouraging data from this research provides a glimmer of hope for a fresh treatment path for patients battling this debilitating ailment, currently having very few effective treatments. The results of the Phase 2 trial indicate substantial advancements in tackling the underlying inflammatory processes leading to muscle deterioration and weight decrease in cancer patients. Such an approach aspires to not only enhance physical function but to also amplify the overall life quality for cancer patients, representing a crucial advancement in oncology care.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Conceptually Defined?

    Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cancer Anorexia-Cachexia Syndrome (CACS) Market Size to Exceed $5.83 Billion by 2029 | Growth and Industry Trends

    Cancer Anorexia-Cachexia Syndrome (CACS) Market Size to Exceed $5.83 Billion by 2029 | Growth and Industry Trends

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Cancer Anorexia-Cachexia Syndrome (CACS) Market Grown from 2024 to 2025?

    The market for cancer anorexia-cachexia syndrome (CACS) has advanced rapidly in the past years. Expected to rise from $3.51 billion in 2024 to $3.89 billion in 2025, it’s predicted to have a compound annual growth rate (CAGR) of 11.0%. The significant growth in the past was due to factors like a higher occurrence of cancer, increased awareness among healthcare professionals, improved focus on cancer patients’ quality of life, growth in clinical trials, and collaboration and partnerships within the pharmaceutical industry.

    What Growth Rate Is Anticipated for the Cancer Anorexia-Cachexia Syndrome (CACS) Market in the Coming Years?

    Anticipations are increasing concerning the quick expansion of the cancer anorexia-cachexia (CACS) market in the forthcoming years. It is projected to escalate to $5.84 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. This predicted surge could be credited to improvements in cancer survival rates, augmenting investments in the fields of oncology supportive care, expansion in personalized medicine, an enhanced emphasis on multimodal treatments, and a swelling healthcare infrastructure. Key trends projected during this period comprise of advancements in palliative care, the development of precision therapies, technological leaps in drug delivery systems, the incorporation of AI in the pharmaceutical developmental process, and personalized medicines.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    Who Are the Leading Companies in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

    What Are the Key Drivers of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The growing incidents of cancer worldwide are set to fuel the expansion of the cancer anorexia-cachexia syndrome market. The term “cancer” constitutes a collection of illnesses defined by unregulated proliferation and metastasis of anomalous cells in the human body. Global cancer incidences are on an upswing due to reasons like aging demographics, lifestyle upheavals, environmental contact, enhanced diagnostic techniques, and heightened consciousness, supplemented by genetic tendencies and specific cancer-related infections. The cancer anorexia-cachexia syndrome (CACS) concentrates on managing the rampant weight loss and malnourishment frequently observed in cancer victims, bettering their life quality and therapy consequences. As an example, in August 2024, as per data released by Macmillan Cancer Support, a charity group based in the UK, cancer was prevalent in more than three million UK citizens, with projections estimating an increment to 3.5 million by 2025, 4 million by 2030 and 5.3 million by 2040. Therefore, the escalating cancer occurrence is enhancing the expansion of the cancer anorexia-cachexia syndrome market. Growth Of The Market Impacted By Surging Healthcare Expenditure

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    What Are the Key Market Segments in the Cancer Anorexia-Cachexia Syndrome (CACS) Industry?

    The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    What Are the Latest Trends in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Leading businesses in the cancer anorexia-cachexia syndrome market are concentrating on the creation of novel solutions, such as monoclonal antibody therapies, to boost treatment effectiveness, advance patient outcomes, and cater to unresolved clinical requirements. These therapies employ lab-manufactured antibodies that are intended to specifically target antigens found on cancer cells, thereby bolstering the immune system to identify and combat them more efficiently. For instance, Pfizer Inc., a pharmaceutical and biotechnology firm based in the US, released encouraging results from a Phase II clinical trial of ponsegromab, a monoclonal antibody that targets Growth/Differentiation Factor 15 (GDF-15), in September 2024. The positive findings from this study represent potential new treatment possibilities for those affected by this incapacitating ailment, where presently, there are limited effective therapies available. The results from the Phase 2 trial indicate substantial advancements in managing the fundamental inflammatory processes linked with muscle and weight loss in cancer patients. The aim of this treatment plan is not just to enhance physical function, but also to improve the overall life quality of patients with cancer, demonstrating a significant advancement in cancer care.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    What Are the Key Regional Markets in the Cancer Anorexia-Cachexia Syndrome (CACS) Industry?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125

    This Report Delivers Insight On:

    1. How big is the cancer anorexia-cachexia syndrome (cacs) market, and how is it changing globally?

    2. Who are the major companies in the cancer anorexia-cachexia syndrome (cacs) market, and how are they performing?

    3. What are the key opportunities and risks in the cancer anorexia-cachexia syndrome (cacs) market right now?

    4. Which products or customer segments are growing the most in the cancer anorexia-cachexia syndrome (cacs) market?

    5. What factors are helping or slowing down the growth of the cancer anorexia-cachexia syndrome (cacs) market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Key Factors Fueling the Growth of the Cancer Anorexia-Cachexia Syndrome (CACS) Market in 2025: Impact Of Rising Cancer Prevalence On The Market

    Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

    What is the Anticipated CAGR of the Cancer Anorexia-Cachexia Syndrome (CACS) Market, and What Factors Will Drive It?

    The market for the cancer anorexia-cachexia syndrome (CACS) has seen a swift expansion in the past few years. The market is forecasted to surge from $3.51 billion in 2024 to $3.89 billion in 2025, progressing at a compound annual growth rate (CAGR) of 11.0%. Factors contributing to the growth experienced in the previous period include a rise in cancer cases, heightened awareness amongst healthcare professionals, an enhanced emphasis on the quality of life for cancer patients, widening clinical trials, and increased collaborations and partnerships within the pharmaceutical industry.

    The market for cancer anorexia-cachexia (CACS) is projected to exhibit swift expansion in the ensuing years, reaching a valuation of $5.84 billion by 2029 with an impressive compound annual growth rate (CAGR) of 10.7%. The anticipated augmentation during this period can be accredited to a rise in cancer survival rates, escalated investments in the support care sector of oncology, the evolution of personalized medicine, an emphasis on multimodal therapies, and an expanding healthcare infrastructure. In the same period, developments in palliative care, the emergence of targeted therapies, technological improvements in drug delivery systems, application of artificial intelligence in drug development, and patient-specific medication are expected to dominate trends.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

    What are the Fundamental Drivers and Innovations Shaping the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    The increasing incidence of cancer is anticipated to stimulate the expansion of the cancer anorexia-cachexia syndrome market. Cancer encompasses a vast array of illnesses defined by unregulated cell proliferation and distribution throughout the body. Global cancer incidence is on the rise due to factors such as an aging demographic, lifestyle modifications, environmental exposure, refined detection procedures, elevated awareness, in addition to genetic susceptibility and infections associated with specific cancers. Cancer Anorexia-Cachexia Syndrome (CACS) responds to this growing cancer incidence by focusing on addressing the extreme weight loss and malnutrition commonly observed in cancer sufferers, thereby enhancing their overall life standard and treatment results. For instance, a report published by Macmillan Cancer Support, a UK-based charity, stated in August 2024 that over 3 million people in the UK are living with cancer, a figure expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the escalating rate of cancer is fueling the growth of the cancer anorexia-cachexia syndrome industry. The Effect Of Rising Health Expenditure On The Market

    How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Segmented?

    The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –

    1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

    2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

    3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

    4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration

    5) By Application: Hospitals, Clinics, Home Care

    Subsegments:

    1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

    2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

    3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

    4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

    5) By Other Indications: Combination Therapies, Supportive Care Interventions

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

    Which Regions Are Driving the Next Phase of the Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth?

    North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Key Trends Are Shaping the Future of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

    Key players in the cancer anorexia-cachexia syndrome market are concentrating on the creation of innovative treatments, such as monoclonal antibody therapies, to improve treatment effectiveness, patient outcomes, and address unknown clinical needs. These therapies utilize antibodies created in a lab to specifically target antigens on cancer cells, which makes the immune system better equipped to identify and combat them. For instance, American pharmaceutical and biotechnology firm, Pfizer Inc., reported promising results from a Stage II clinical trial of ponsegromab, a monoclonal antibody that targets the Growth/Differentiation Factor 15 (GDF-15) in September 2024. This encouraging data provides potential for a fresh therapeutic pathway for patients enduring this devastating illness, as there are presently very few efficient treatments available. The Phase 2 trial data indicates significant advancement in tackling the inflammation processes that lead to muscle wastage and weight loss in cancer patients. This methodology is geared towards not only improving physical capabilities, but also escalating the overall living standards for cancer patients, signifying a crucial advancement in cancer treatment.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

    How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Defined and What Are Its Core Parameters?

    Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model